Literature DB >> 6959194

Kinetics of citalopram in test animals; drug exposure in safety studies.

K Fredricson Overø.   

Abstract

1. Plasma levels of citalopram and its metabolites were assayed after single oral and intravenous doses to baboons (4 mg/kg), dogs (1, 4, 5, and 10 mg/kg), rats (8 mg/kg), and mice (24 mg/kg). Kinetic parameters were estimated. 2. Half-lives were short (estimate for baboon 3, dog 3 1/2-8, rat 3, and mouse 1 1/2 hours) and systemic plasma clearance high (baboon 39, dog 37-14, male rat 82, female rat 103, male mouse 87, and female mouse 116 ml/min/kg body weight). Considerable first-pass metabolism was demonstrated. 3. Drug level data were obtained in long-term safety studies in dogs (1, 3, and 8 mg/kg), rats (32 and 320 mg/kg), and mice (640 mg/kg). The high-dose citalopram level in dogs and rats exceeded that of patients by a factor of 10; the factor for mice was 40.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6959194     DOI: 10.1016/s0278-5846(82)80180-2

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  23 in total

1.  Antidepressant response to chronic citalopram treatment in eight inbred mouse strains.

Authors:  Jianwei Jiao; Angela M Nitzke; Demetrios G Doukas; Mariel P Seiglie; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

2.  In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats.

Authors:  F C Kugelberg; G Apelqvist; B Carlsson; J Ahlner; F Bengtsson
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram.

Authors:  L Arborelius; G G Nomikos; P Grillner; P Hertel; B B Höök; U Hacksell; T H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

4.  Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain.

Authors:  Y Chaput; C de Montigny; P Blier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-08       Impact factor: 3.000

5.  Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo.

Authors:  S B Auerbach; S Hjorth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

Review 6.  Citalopram and cardiac toxicity.

Authors:  M J Cooke; W S Waring
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

7.  Facilitation of serotonin signaling by SSRIs is attenuated by social isolation.

Authors:  Elyse C Dankoski; Kara L Agster; Megan E Fox; Sheryl S Moy; R Mark Wightman
Journal:  Neuropsychopharmacology       Date:  2014-07-01       Impact factor: 7.853

8.  Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels.

Authors:  L Bjerkenstedt; L Flyckt; K F Overø; O Lingjaerde
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram.

Authors:  J Hyttel; K F Overø; J Arnt
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.

Authors:  Cedric Mombereau; Tamar L Gur; Jennifer Onksen; Julie A Blendy
Journal:  Int J Neuropsychopharmacol       Date:  2009-12-14       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.